CAS: 215303-72-3; 4-(4-(4-Fluorophenyl)-1-(3-Phenylpropyl)-5-(Pyridin-4-yl)-1H-Imidazol-2-yl)But-3-Yn-1-Ol
该化合物是一种复杂的有机化合物,其特征是其蛋白色核核心,是五人组成的含有氮原子的热循环结构.该化合物具有多种功能组,包括丁诺丁醇杂醇和氟联苯组,有助于其潜在的生物活动.一个丙烯环的存在会加强其脂性,并可能影响其与生物目标的互动.该化合物的结构表明其在医药化学中的潜在应用,特别是在针对特定受体或酶的药品开发中的潜在应用.该化合物的独特的亚成组体安排还可能产生特定的药性皮肤特性,例如溶性与稳定性.许多合成有机化合物,了解其在各种条件下的再活性,稳定性和潜在毒性对于其应用至关重要.
- 英文名称4-(4-(4-Fluorophenyl)-1-(3-Phenylpropyl)-5-(Pyridin-4-yl)-1H-Imidazol-2-yl)But-3-Yn-1-Ol
- 中文名称4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑
- IUPAC名称4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol
- 其它别名4-[4-(4-Fluorophenyl)-1-(3-Phenylpropyl)-5-(4-Pyridinyl)-1H-Imidazol-2-Yl]-3-Butyn-1-Ol
- CAS编号215303-72-3
- MFCD编号:MFCD11840606
- FDA UNII编号:MXN26D3ZUN
- 分子式:C27H24FN3O分子量:425.51
- 产品CID: 1118234
- 产品分类医药中间体 → 吡啶类化合物
物理性质
MSDS等安全信息
上下游产品
3-Butyn-1-ol合成工艺路线路线简述
📜4-(4-Fluorophenyl)-2-Iodo-1-(3-Phenylpropyl)-5-(Pyridin-4-yl)Imidazole,3-丁炔-1-醇置于3-丁炔-1-醇体系中,化学反应生成Jnj 3026582; 4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑
参考文献:Substituted Imidazoles Useful In The Treatment Of Inflammatory Disease
标题:Substituted Imidazoles Useful In The Treatment Of Inflammatory Disease
摘要:本发明涉及一系列取代咪唑的化合物,其化学式为i ##str1## 包含它们的药物组成物以及用于制造它们的中间体.本发明的化合物抑制多种炎症细胞因子的产生,并可用于治疗与过度产生炎症细胞因子相关的疾病.
海关参考信息
- 2901292000-乙炔
2902600000-乙苯
2905121000-正丙醇
2933310010-吡啶 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9982006-B2
优先权日:2014-08-21
标题:2′-chloro aminopyrimidinone and pyrimidine dione nucleosides
发明人：CLARKE MICHAEL O'NEIL HANRAHAN; MACKMAN RICHARD L; SIEGEL DUSTIN
权利人:GILEAD SCIENCES INC
摘要:Provided herein are formulations, methods and substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds.
专利号:US-9828388-B2
优先权日:2014-07-28
标题:Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections
发明人：CLARKE MICHAEL O'NEIL HANRAHAN; MACKMAN RICHARD L; SIEGEL DUSTIN
权利人:GILEAD SCIENCES INC
摘要:Provided herein are formulations, methods and substituted thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidine compounds.
专利号:US-9701682-B2
优先权日:2013-11-11
标题:Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
发明人：CLARKE MICHAEL O'NEIL HANRAHAN; DOERFFLER EDWARD; MACKMAN RICHARD L; SIEGEL DUSTIN
权利人:GILEAD SCIENCES INC
摘要:Provided herein are formulations, methods and substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther. 1999 Nov;291(2):680-7. 150(13):1226-1235. doi: 10.1017/S0031182023000999. Epub 2023 Oct 20.
3: Westra J, Limburg PC, de Boer P, van Rijswijk MH. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis. 2004 Nov;63(11):1453-9. doi: 10.1136/ard.2003.013011.
4: Bai YY, Wang L, Chang D, Zhao Z, Lu CQ, Wang G, Ju S. Synergistic Effects of Transplanted Endothelial Progenitor Cells and RWJ 67657 in Diabetic Ischemic Stroke Models. Stroke. 2015 Jul;46(7):1938-46. doi: 10.1161/STROKEAHA.114.008495. Epub 2015 Jun 4. 43(4):406-13. doi: 10.1177/0091270002250615. 127(2):337-43. doi: 10.1046/j.1365-2249.2002.01765.x.
合成参考文献
参考文献:10.1124/mol.119.115964
摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
参考文献:10.1177/0091270002250615
摘要:Parasrampuria DA, de Boer P, Desai-Krieger D, Chow AT, Jones CR. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol. 2003 Apr;43(4):406–13. doi: 10.1177/0091270002250615.
📝 需求与反馈
尽可能描述清楚需求与问题信息
